PharmaTelevision - ChinaBio LLC: China as one of biopharma's biggest players

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: ChinaBio LLC: China as one of biopharma's biggest players

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Greg Scott, President and Founder of ChinaBio LLC.

They discuss:

• Greg's transition from a management consultant to founding ChinaBio LLC
• the pace of technology and patents in China
• intellectual property and legal protection over techs
• the difference between bio companies in the west and in China
• the funding system in China
• innovation and Genentech’s involvement in adopting new breakthrough therapeutic approaches
• advice on how other firms should approach the Chinese market
• China's future as the world's number one developer of new drugs

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Greg Scott's transition from a management consultant to founding ChinaBio LLC

Fintan Walton:

Hello and welcome to PharmaTelevision news review here in San Francisco at BioPharm America. On this show I have Greg Scott, who is President and Founder of ChinaBio based in Shanghai. Welcome to the show.

Greg Scott:

Thanks very much Fintan. It's pleasure to be here.

Fintan Walton:

Greg, you've founded ChinaBio which is a specialty house if I could describe it a consultancy and information provider based in China, how did an American end up in Shanghai doing the type of thing that you're doing?

Greg Scott:

Well it's actually a pretty interest story. I went to China in fact my first trip to Asia was in November 2006 and by tour of China ended in Shanghai and I sneaked in one business meeting in Shanghai and discovered what is now a Zhangjiang Hi-Tech Park which houses about 500 biotech companies and I didn't even know there was a biotech industry in China. So I decided right there and that I have to go back and learn more about that. So I went back in January 2007 and there basically have been there half time, and then a little over a year ago I moved there and there in a full time, so

Fintan Walton:

So it was a journey of discovery and your background is in this, in the pharmaceutical industry?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Greg Scott

President and Founder ChinaBio LLC

Mr. Scott has helped launch over thirty life science startups in the U.S. and China as a founder, investor and advisor. He founded the ChinaBio LLC in January 2007 to help fund and mentor early stage life science companies in China, and provide consulting and research services to pharma and biotech companies with business interests in China. Mr. Scott is also the president and co-founder of Life Science Angels, an angel investment group that has funded 30 biotechnology and medical device companies since 2005, and executive editor of ChinaBio Today. He is also a strategic adviser to ChinaSF, an initiative of the Mayor of San Francisco to connect China and San Francisco business interests. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and was co-founder of a 200-person consulting firm. Mr. Scott attended University of Missouri, where he studied mathematics, microbiology and computer science.

ChinaBio LLC

ChinaBio By the end of 2008, less than two years from its inception, ChinaBio had organized five major conferences in China, including four ChinaBio Investor Forums and the BioCapital China Summit in Beijing. For 2009, it has plans for another six major events, including the first ChinaBio Partnering Forum in Shanghai in June, and its first US event in September in San Francisco. ChinaBio has also, also worked with some of the world's most respected pharma and biotech companies, including Roche and Pfizer, and helped China biomedical companies raise over $60M US. Its in-house research staff tracks China's biotech industry including novel technology development, clinical trial activity, VC investments and M&A and IPO activity. This information gives ChinaBio and its client's critical insights into the direction of the industry and how China will impact the future of the global biopharma industry.